Sionna Therapeutics (NASDAQ:SION) Cut to “Neutral” at Wedbush

Posted by Geri Gentry on Aug 13th, 2026

Wedbush cut shares of Sionna Therapeutics (NASDAQ:SION – Free Report) from an outperform rating to a neutral rating in a report released on Monday morning, Marketbeat Ratings reports. The brokerage currently has $5.00 price target on the stock.

A number of other equities analysts have also weighed in on the stock. Guggenheim lifted their price target on shares of Sionna Therapeutics from $50.00 to $60.00 and gave the company a “buy” rating in a report on Friday, August 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Sionna Therapeutics in a report on Wednesday, August 5th. Stifel Nicolaus reaffirmed a “hold” rating and issued a $7.00 target price on shares of Sionna Therapeutics in a research report on Monday. BTIG Research reiterated a “buy” rating and issued a $58.00 target price on shares of Sionna Therapeutics in a report on Wednesday, May 13th. Finally, Freedom Capital downgraded Sionna Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, May 20th. One investment analyst has rated the stock with a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $42.22.

Read Our Latest Report on Sionna Therapeutics

Sionna Therapeutics Stock Performance

SION opened at $6.25 on Monday. The company’s 50 day simple moving average is $40.38 and its 200 day simple moving average is $39.67. Sionna Therapeutics has a 1 year low of $4.01 and a 1 year high of $54.97. The stock has a market capitalization of $282.56 million, a PE ratio of -2.87 and a beta of 1.33.

Sionna Therapeutics (NASDAQ:SION – Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.02). As a group, sell-side analysts expect that Sionna Therapeutics will post -2.65 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Sionna Therapeutics news, Director Peter A. Thompson sold 115,844 shares of Sionna Therapeutics stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $45.50, for a total transaction of $5,270,902.00. Following the transaction, the director directly owned 2,555,877 shares of the company’s stock, valued at $116,292,403.50. The trade was a 4.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Orbimed Advisors Llc sold 115,844 shares of the business’s stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $45.50, for a total transaction of $5,270,902.00. Following the sale, the director owned 2,555,877 shares of the company’s stock, valued at approximately $116,292,403.50. This represents a 4.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 403,726 shares of company stock worth $18,259,354. 5.10% of the stock is currently owned by corporate insiders.

Institutional Trading of Sionna Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the business. UBS Group AG boosted its holdings in Sionna Therapeutics by 91.1% in the 4th quarter. UBS Group AG now owns 89,177 shares of the company’s stock worth $3,669,000 after acquiring an additional 42,511 shares during the period. Vanguard Group Inc. boosted its holdings in Sionna Therapeutics by 3.7% in the fourth quarter. Vanguard Group Inc. now owns 1,184,951 shares of the company’s stock worth $48,749,000 after purchasing an additional 41,797 shares during the period. Jennison Associates LLC boosted its holdings in Sionna Therapeutics by 11.8% in the fourth quarter. Jennison Associates LLC now owns 1,115,278 shares of the company’s stock worth $45,883,000 after purchasing an additional 117,903 shares during the period. Candriam S.C.A. bought a new stake in Sionna Therapeutics during the first quarter valued at $9,494,000. Finally, Eventide Asset Management LLC bought a new stake in Sionna Therapeutics during the fourth quarter valued at $26,290,000.

Key Headlines Impacting Sionna Therapeutics

Here are the key news stories impacting Sionna Therapeutics this week:

Positive Sentiment: The stock’s rebound may reflect bargain hunting and short-term volatility following the steep selloff, although no new positive clinical data were reported.
Neutral Sentiment: Analyst opinion has broadly converged around a more cautious stance. Royal Bank of Canada upgraded SION to “Sector Perform,” while Stifel Nicolaus assigned a “Hold” rating. Royal Bank of Canada upgrade
Negative Sentiment: Sionna reported that its Phase 2a PreciSION CF trial of lead candidate SION-719 failed to achieve its key endpoint for sweat-chloride reduction. The drug will not advance as an add-on therapy, severely damaging the company’s near-term cystic-fibrosis development prospects. Sionna halts lead cystic fibrosis drug
Negative Sentiment: The clinical failure erased roughly 90% of SION’s market value and removed a potential competitive threat to Vertex Pharmaceuticals, whose shares benefited from the news. Vertex rises as Sionna trial fails
Negative Sentiment: Several firms reduced their ratings, including Lifesci Capital and JonesTrading to “Hold,” Wedbush to “Neutral,” Raymond James to “Market Perform,” and BTIG and Guggenheim to lower ratings. These actions signal reduced confidence after the trial result. Wedbush downgrade
Negative Sentiment: Levi & Korsinsky announced a pending investor investigation into potential securities-law violations related to disclosures that allegedly indicated SION-719 was on track before the failed trial outcome. The investigation adds legal and reputational risk. Sionna investor investigation notice

About Sionna Therapeutics

(Get Free Report)

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.